TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01953237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedActive
Description: Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Study: NCT04167462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on Specified Days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on Specified days
Study: NCT03171870

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: high resolution computed tomography
Description: high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
Study: NCT03938870

Intervention type: OTHER
Intervention: L-Leucine 13C6

Intervention type: OTHER
Intervention: L-Leucine 13C6
Study: NCT00581139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Preparation Program (Child Life Specialist)
Description: This group will receive the standard preoperative visit to the hospital with Child Life intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.5 mg/kg oral midazolam
Study: NCT03938870

Intervention type: OTHER
Intervention: L-Leucine 13C6
Study: NCT04657900

Intervention type: OTHER
Intervention: Observational
Description: Observational - no intervention given
Study: NCT02606253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorothiazide
Description: Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
Study: NCT03650075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-S-2525
Description: The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MG-S-2525
Description: The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MG-S-2525
Description: The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
Study: NCT02649699

Intervention type: OTHER
Group type: OTHER
Intervention: 3D MRI Scans
Description: Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
Study: NCT03718000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW)
Description: DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
Study: NCT00559715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg intravitreally monthly/on demand

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg intravitreally monthly/on demand
Study: NCT01866592

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
Study: NCT02441283

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ABT-493
Description: ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ABT-530
Description: ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Study: NCT04426032

Intervention type: DIAGNOSTIC_TEST
Intervention: Renal Doppler Ultrasound
Description: Measurement of Renal resistive index

Intervention type: DIAGNOSTIC_TEST
Intervention: Renal Doppler Ultrasound
Description: Measurement of Renal resistive index
Study: NCT03279315

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iodized table salt, non-iodized table salt
Description: During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
Study: NCT01543191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR118
Description: low dose and high dose for 3 doses, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PUR118
Description: low dose and high dose for 3 doses, BID
Study: NCT02806999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine; Insulin
Description: Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
Study: NCT03110276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: 10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
Study: NCT01995201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD
Description: non-biological disease-modifying antirheumatic drugs at stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD
Description: non-biological disease-modifying antirheumatic drugs at stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD
Description: non-biological disease-modifying antirheumatic drugs at stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously (SC) qw, Weeks 1-24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg SC qw or q2w, Weeks 24-48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg SC qw, Weeks 24-48
Study: NCT01857518

Intervention type: OTHER
Group type: OTHER
Intervention: -Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI
Description: * Visit V1: Diagnostic and clinical assessments~* Visit V2: psycho-behavioral assessment and neuroimaging~* Visit V3: Diagnostic and clinical assessments~* Visit V4: psycho-behavioral assessment and neuroimaging

Intervention type: OTHER
Group type: OTHER
Intervention: -Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI
Description: * Visit V1: Diagnostic and clinical assessments~* Visit V2: psycho-behavioral assessment and neuroimaging~* Visit V3: Diagnostic and clinical assessments~* Visit V4: psycho-behavioral assessment and neuroimaging
Study: NCT04557774

Intervention type: OTHER
Intervention: Cognitive function test
Description: Laboratory and imaging test~* Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~* Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive
Study: NCT01449214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmarking
Description: Landmark-guided technique
Study: NCT00581139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Presence during Induction of Anesthesia
Description: One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PPIA preparation program PLUS Midazolam premedication
Description: Subjects in this group will receive both interventions 2 and 3.
Study: NCT01674491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black soy peptide
Description: black soy peptide: 4.5g/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: black soy peptide
Description: black soy peptide: 4.5g/day for 8 weeks
Study: NCT04023461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVAC GOLD catheter ablation
Description: Isolation of pulmonary veins using PVAC GOLD catheter.
Study: NCT01067183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: portable biofeedback tool and relaxation breathing technique
Description: The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
Study: NCT02152683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renova
Description: Low- Intensity Shockwave

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renova
Description: Low- Intensity Shockwave
Study: NCT03708991

Intervention type: DIAGNOSTIC_TEST
Intervention: IVF combined with PGT-A
Description: trophectoderm biopsy to test the ploidy state of the IVF embryos

Intervention type: DIAGNOSTIC_TEST
Intervention: ICSI combined with PGT-A
Description: trophectoderm biopsy to test the ploidy state of the ICSI embryos
Study: NCT03584919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: patients received oral doxycycline 100 milgrams bid for 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime Axetil 500Mg Tab
Description: patients received cefuroxime axetil 500 milgrams bid for 15 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control subjects
Description: no intervention
Study: NCT02237378

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET scan
Description: Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
Study: NCT01746615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: retinal vessel diameter \& oxygen saturation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: retinal vessel diameter \& oxygen saturation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)
Description: retinal blood velocity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)
Description: retinal blood velocity
Study: NCT03235128

Intervention type: DIAGNOSTIC_TEST
Intervention: ‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.
Description: Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
Study: NCT00471120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P2x7 assay
Description: compare P2X7 assay to biopsy
Study: NCT01332162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Description: All patients will be pacing during two years

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Pacing
Description: No Pacing during the first year. In the second year all patients will be pacing
Study: NCT03235128

Intervention type: DIAGNOSTIC_TEST
Intervention: ‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.
Description: Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood

Intervention type: DIAGNOSTIC_TEST
Intervention: ‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.
Description: Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood

Intervention type: DIAGNOSTIC_TEST
Intervention: ‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.
Description: Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
Study: NCT02252120

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme
Study: NCT02518269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroplasty
Description: Hip Arthroplasty comparing 3 different bearings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroplasty
Description: Hip Arthroplasty comparing 3 different bearings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroplasty
Description: Hip Arthroplasty comparing 3 different bearings.
Study: NCT01431742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Buprenorphine
Description: buccal soluble film; applied to the buccal mucosa twice daily
Study: NCT01294540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: E2609
Description: E2609 orally at varying ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02842099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA or TAC
Description: Taxol, Epirubincin, with or without Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA or TAC
Description: Taxol, Epirubincin, with or without Cyclophosphamide
Study: NCT02252120

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube
Study: NCT04480762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of the SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of the SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of the SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of the SHR-1703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of the SHR-1703
Study: NCT00058955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium oxybate, triazolam and pentobarbital
Description: sodium oxybate, triazolam and pentobarbital
Study: NCT02842099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X
Description: Capecitabine
Study: NCT00058955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium oxybate, triazolam and pentobarbital
Description: sodium oxybate, triazolam and pentobarbital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium oxybate, triazolam and pentobarbital
Description: sodium oxybate, triazolam and pentobarbital

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium oxybate, triazolam and pentobarbital
Description: sodium oxybate, triazolam and pentobarbital
Study: NCT03368287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit One, the activity tracker
Description: Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
Study: NCT02631083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast, lunch, snack and dinner
Description: These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast, lunch, snack and dinner
Description: These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
Study: NCT03660033

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG in delivery room
Description: See arm/group discussions
Study: NCT03454217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Postoperative pain treatment with oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Postoperative pain treatment with tramadol
Study: NCT00875849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04165161

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: search for a patent foramen ovale
Description: Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: search for a patent foramen ovale
Description: Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: search for a patent foramen ovale
Description: Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: search for a patent foramen ovale
Description: Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;
Study: NCT00569361

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of nasal epithelial cells
Description: Collection of nasal epithelial cells by brushing